Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922-Reference-Cited by-同舟云学术

Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922

Published:2016-07-06 Issue:31 Volume:7 Page:49597-49610
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Wang Chun Yan¹²,Guo Su Tang¹²,Wang Jia Yu¹,Yan Xu Guang¹,Farrelly Margaret¹,Zhang Yuan Yuan³,Liu Fen¹,Yari Hamed¹,La Ting¹,Lei Fu Xi¹,Jin Lei³,Zhang Xu Dong¹,Jiang Chen Chen³

Affiliation:

1. School of Biomedical Sciences and Pharmacy, The University of Newcastle, NSW, Australia

2. Department of Molecular Biology, Shanxi Cancer Hospital and Institute, Taiyuan, Shanxi, China

3. School of Medicine and Public Health, The University of Newcastle, NSW, Australia

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancer;Frontiers in Molecular Biosciences;2023-01-19

2. Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer;Drug Resistance Updates;2022-12

3. The Chaperone System in Salivary Glands: Hsp90 Prospects for Differential Diagnosis and Treatment of Malignant Tumors;International Journal of Molecular Sciences;2022-08-18

4. The Therapeutic Potential of Targeting Hsp90-Cdc37 Interactions in Several Diseases;Current Drug Targets;2022-08

5. Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo;Biomedicines;2022-03-07